LizaAnnSquiresMD

Summary

• Liza Squires, MD currently serves as the Chief Medical Officer at Neuren Pharmaceuticals. Her career has focused on the development of novel therapeutics for diseases of the Central Nervous System that affect children. Over the past decade, she has concentrated on genetically targeted treatments for children. Liza began her career in academic, hospital-based child neurology where the unmet need for therapeutic options drew her to a career in drug development. Over the past 20 years, she has held positions of increasing responsibilities in both early and late-stage development at Johnson and Johnson, Shire Pharmaceuticals, Lumos Pharma, Aevi Genomic Medicine and Origin Biosciences. She has led and contributed to multiple NDAs and sNDAs resulting in global regulatory approvals for Topamax® (topiramate), Daytrana® (methylphenidate transdermal system), Vyvanse® (lisdexamfetamine dimesylate), Intuniv® (guanfacine ER) and Nulibry® (fosdenopterin). Liza is the author of many referenced publications in peer-reviewed journals and has been active in advocacy groups for the advancement of pediatric therapeutics. She received her B.S. from the University of Michigan and M.D. from Michigan State University. She trained in general pediatrics at Yale University and did her residency in Child Neurology at Massachusetts General Hospital. Liza is board certified in General Pediatrics and Neurology with Special Competence in Child Neurology.